Header Logo

DEBORAH A KUBAN

TitleProfessor
InstitutionMD Anderson
DepartmentRadiation Oncology
Address1220 Holcombe Blvd
Houston TX 77030-4004
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Patel SA, Patil D, Smith J, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Michalski JM, Wood DP, Hembroff LA, Spratt DE, Wei JT, Sandler HM, Hamstra DA, Pisters L, Kuban D, Regan MM, Wagner A, Crociani CM, Kaplan I, Sanda MG, Chang P, PROST-QA/RP2 Consortium. Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA Netw Open. 2024 Oct 01; 7(10):e2440747. PMID: 39446326; PMCID: PMC11581678.
      Citations:    Fields:    Translation:Humans
    2. Fang AM, Chapin BF, Shi CW, Sun J, Qayyum A, Kundra V, Corn PG, Kuban DA, Ravizzini GC, Surasi DSS, Ma J, Bathala TK. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2024 Sep 17. PMID: 39289537.
      Citations:    Fields:    
    3. Kouzy R, Ludmir EB, Hoffman KE, Jhingran A, Kuban DA. In Reply to Akhtar et al. Pract Radiat Oncol. 2024 Sep-Oct; 14(5):466-467. PMID: 39218529.
      Citations:    Fields:    
    4. Sosa AJ, Rooney MK, Thames HD, Sanders JW, Swanson DM, Choi SL, Nguyen QN, Mok H, Kuban DA, Ron Zhu X, Shah S, Mayo LL, Hoffman KE, Tang C, McGuire SE, Sahoo N, Zhang X, Lee AK, Pugh TJ, Mahmood U, Davis JW, Chapin BF, Corn P, Kudchadker R, Ausat N, Frank SJ. Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clin Transl Radiat Oncol. 2024 Sep; 48:100822. PMID: 39188999; PMCID: PMC11345681.
      Citations:    
    5. Ludmir EB, Hoffman KE, Jhingran A, Kouzy R, Ip MP, Sturdevant L, Ning MS, Minsky BD, McAleer MF, Chronowski GM, Arzu IY, Reed VK, Garg AK, Roberts T, Eastwick GA, Olson MR, Selek U, Gabel M, Koong AC, Kupferman ME, Kuban DA. Implementation and Efficacy of a Large-Scale Radiation Oncology Case-Based Peer-Review Quality Program across a Multinational Cancer Network. Pract Radiat Oncol. 2024 May-Jun; 14(3):e173-e179. PMID: 38176466.
      Citations: 1     Fields:    Translation:Humans
    6. De B, Lowenstein LM, Corrigan KL, Andring LM, Kuban DA, Cantor SB, Volk RJ, Hoffman KE. Patients' Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer. MDM Policy Pract. 2022 Jul-Dec; 7(2):23814683221137752. PMID: 36405544; PMCID: PMC9669695.
      Citations:    
    7. Thaker NG, Kudchadker RJ, Incalcaterra JR, Bathala TK, Kaplan RS, Agarwal A, Kuban DA, Frank BD, Das P, Feeley TW, Frank SJ. Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing. Brachytherapy. 2022 Jan-Feb; 21(1):49-54. PMID: 34389265.
      Citations:    Fields:    Translation:Humans
    8. De B, Kuban DA, Tang C. Multidisciplinary clinics in prostate cancer. Oncotarget. 2021 Jul 20; 12(15):1553-1554. PMID: 34316333; PMCID: PMC8310670.
      Citations:    Fields:    
    9. Johnston PA, Kitchens JL, LaBree K, Powers CA, Segovia JH, Viles J, Mshindi Walker M, Kuban DA. COVID-19 and Oncology: Operationalizing Best Practices Across Collaborative Health Systems. Clin J Oncol Nurs. 2020 08 01; 24(4):444-447. PMID: 32678371.
      Citations:    Fields:    Translation:HumansPHPublic Health
    10. Boyce-Fappiano D, Bathala TK, Ye R, Pasalic D, Gjyshi O, Pezzi TA, Noticewala SS, McGinnis GJ, Maroongroge S, Kuban DA, Nguyen QN, McGuire SE, Hoffman KE, Choi S, Tang C, Kudchadker RJ, Frank SJ. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy. 2020 Sep - Oct; 19(5):574-583. PMID: 32682778.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    11. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985. PMID: 32353391; PMCID: PMC10018317.
      Citations: 1     Fields:    Translation:Humans
    12. Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292. PMID: 32298794; PMCID: PMC7395481.
      Citations: 2     Fields:    Translation:Humans
    13. Tang C, Hoffman K, Kuban D. Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer. Cancer. 2020 06 15; 126(12):2939-2940. PMID: 32160318.
      Citations: 1     Fields:    Translation:Humans
    14. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255. PMID: 32191331; PMCID: PMC7082722.
      Citations: 8     Fields:    Translation:Humans
    15. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97. PMID: 31899230; PMCID: PMC7141963.
      Citations: 2     Fields:    Translation:Humans
    16. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514. PMID: 31742674; PMCID: PMC6980273.
      Citations: 7     Fields:    Translation:Humans
    17. Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 11; 124(5):811-819. PMID: 31009137.
      Citations: 11     Fields:    Translation:Humans
    18. Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, Augustyn AA, Frank SJ, Choi S, Hoffman KE, Nguyen QN, McGuire SE, Pollack A, Anscher MS. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):790-797. PMID: 30836166; PMCID: PMC6579684.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    19. Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, Lee AK, McGuire SE, Nguyen Q, Pugh TJ, Frank SJ, Kudchadker RJ, Du W, Kuban DA. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018 10 10; 36(29):2943-2949. PMID: 30106637; PMCID: PMC6804854.
      Citations: 32     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    20. Kuban DA, Carvalho ?T, Baccaglini W, Claros OR, Chen FK, Kayano PP, Lemos GC, Weltman E, Carneiro A. Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis. Acta Oncol. 2018 Aug; 57(8):1003-1010. PMID: 29882448.
      Citations: 9     Fields:    Translation:Humans
    21. Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2018 Jun; 41(6):558-567. PMID: 27635624.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    22. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548. PMID: 28941030.
      Citations: 8     Fields:    Translation:Humans
    23. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382. PMID: 29229325.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    24. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017 09; 15(9):1111-1120. PMID: 28874596.
      Citations: 19     Fields:    Translation:HumansAnimals
    25. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901; PMCID: PMC6126916.
      Citations: 6     Fields:    Translation:Humans
    26. Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, Choi S, Lee AK, Schlembach PJ, Frank SJ, McGuire SE, Hoffman KE. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):249-258. PMID: 29114589; PMCID: PMC5605303.
      Citations: 10     
    27. Holliday EB, Kuban DA, Levy LB, Bolukbasi Y, Master P, Choi S, Nguyen Q, McGuire SE, Mahmood U, Frank SJ, Hoffman KE. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis. 2017 12; 20(4):389-394. PMID: 28462945.
      Citations: 1     Fields:    Translation:Humans
    28. Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, Litwin MS, Kuban DA, Hembroff L, Regan MM, Chang P, Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium, Michalski JM. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):304-317. PMID: 28463150; PMCID: PMC5493021.
      Citations: 9     Fields:    Translation:Humans
    29. Pugh TJ, Choi S, Nogueras-Gonzalaez GM, Nguyen QN, Mahmood U, Frank SJ, Mathai B, Zhu XR, Sahoo N, Gillin M, Kuban DA, Hoffman KE, McGuire SE, Lee AK. Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. Int J Part Ther. 2016; 3(1):27-36. PMID: 31772973; PMCID: PMC6871578.
      Citations: 2     
    30. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Hamstra DA, Spratt DE, Garin O, Ferrer M. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):770-777. PMID: 27663760.
      Citations: 2     Fields:    Translation:Humans
    31. Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE, Bian SX. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73. PMID: 24732810.
      Citations:    Fields:    Translation:Humans
    32. Ludwig MS, Kuban DA, Strom SS, Du XL, Lopez DS, Yamal JM. Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. Am J Mens Health. 2017 Jan; 11(1):73-81. PMID: 25891393; PMCID: PMC5675176.
      Citations: 3     Fields:    
    33. Thaker NG, Sturdevant L, Jhingran A, Das P, Delclos ME, Gunn GB, McAleer MF, Tereffe W, Choi SL, Frank SJ, Simeone WJ, Martinez W, Hahn SM, Famiglietti R, Kuban DA. Assessing the Quality of a Radiation Oncology Case-Based, Peer-Review Program in an Integrated Academic and Community Cancer Center Network. J Oncol Pract. 2016 Apr; 12(4):e476-86. PMID: 26931402.
      Citations: 3     Fields:    Translation:Humans
    34. Thaker NG, Pugh TJ, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orio PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ. Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy. 2016 May-Jun; 15(3):274-282. PMID: 26916105; PMCID: PMC5502102.
      Citations: 6     Fields:    Translation:Humans
    35. Le YL, McFall SL, Byrd TL, Volk RJ, Cantor SB, Kuban DA, Mullen PD. Is "Active Surveillance" an Acceptable Alternative?: A Qualitative Study of Couples' Decision Making about Early-Stage, Localized Prostate Cancer. Narrat Inq Bioeth. 2016; 6(1):51-61. PMID: 27346824; PMCID: PMC5176358.
      Citations: 5     Fields:    Translation:Humans
    36. Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA, PROSTQA Study Consortium. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84. PMID: 26276528.
      Citations: 19     Fields:    Translation:Humans
    37. Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015 Oct 01; 93(2):294-302. PMID: 26209502; PMCID: PMC4719152.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    38. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275; PMCID: PMC4808616.
      Citations: 17     Fields:    Translation:Humans
    39. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Mar; 117(3):469-77. PMID: 25714186; PMCID: PMC4547910.
      Citations: 39     Fields:    Translation:Humans
    40. Ludwig MS, Kuban DA, Strom SS, Du XL, Lopez DS, Yamal JM. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation. BMC Cancer. 2015 Mar 27; 15:190. PMID: 25885406; PMCID: PMC4472156.
      Citations:    Fields:    Translation:Humans
    41. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9. PMID: 25023650; PMCID: PMC4372187.
      Citations: 48     Fields:    Translation:Humans
    42. Thaker NG, Kudchadker RJ, Swanson DA, Albert JM, Mahmood U, Pugh TJ, Boehling NS, Bruno TL, Prestidge BR, Crook JM, Cox BW, Potters L, Moran BJ, Keyes M, Kuban DA, Frank SJ. Establishing high-quality prostate brachytherapy using a phantom simulator training program. Int J Radiat Oncol Biol Phys. 2014 Nov 01; 90(3):579-86. PMID: 25151539.
      Citations: 7     Fields:    Translation:Humans
    43. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8. PMID: 24994920; PMCID: PMC4413899.
      Citations: 3     Fields:    Translation:Humans
    44. Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE. Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014 Dec; 192(6):1650-6. PMID: 24931803; PMCID: PMC10988984.
      Citations: 16     Fields:    Translation:Humans
    45. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e239-46. PMID: 25407875.
      Citations: 8     Fields:    Translation:Humans
    46. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84. PMID: 24661661.
      Citations: 47     Fields:    Translation:HumansPHPublic Health
    47. Bilen MA, Hariri H, Leon C, Guo CC, Kuban DA, Pisters LL, Tu SM. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature. Clin Genitourin Cancer. 2014 Aug; 12(4):e147-50. PMID: 24674785; PMCID: PMC4104212.
      Citations: 1     Fields:    Translation:Humans
    48. Ballo MT, Chronowski GM, Schlembach PJ, Bloom ES, Arzu IY, Kuban DA. Prospective peer review quality assurance for outpatient radiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):279-284. PMID: 25194094.
      Citations: 9     Fields:    Translation:Humans
    49. Volk RJ, McFall SL, Cantor SB, Byrd TL, Le YC, Kuban DA, Mullen PD. 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Psychooncology. 2014 Apr; 23(4):467-72. PMID: 24243777; PMCID: PMC3983844.
      Citations: 26     Fields:    Translation:Humans
    50. Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal C, Litwin M, Kuban D, Hembroff L, Chang P, Sanda MG, PROSTQA Consortium. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology. 2013 Dec; 82(6):1363-8. PMID: 24139340; PMCID: PMC3904352.
      Citations: 10     Fields:    Translation:Humans
    51. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53. PMID: 24139077; PMCID: PMC4086944.
      Citations: 16     Fields:    Translation:Humans
    52. Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K, Kuban D, Lee A. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014 Mar-Apr; 13(2):157-62. PMID: 24050892.
      Citations: 20     Fields:    Translation:Humans
    53. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):346-51. PMID: 23939133.
      Citations: 1     Fields:    Translation:Humans
    54. Hoffman KE, Kuban DA. Lymph node-positive prostate cancer: the benefit of local therapy. Oncology (Williston Park). 2013 Jul; 27(7):655, 660-1. PMID: 23977760.
      Citations: 1     Fields:    Translation:Humans
    55. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71. PMID: 23798338.
      Citations: 17     Fields:    Translation:Humans
    56. Li X, Quan EM, Li Y, Pan X, Zhou Y, Wang X, Du W, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A fully automated method for CT-on-rails-guided online adaptive planning for prostate cancer intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):835-41. PMID: 23726001.
      Citations: 8     Fields:    Translation:HumansPHPublic Health
    57. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):594-615. PMID: 23667209; PMCID: PMC4042432.
      Citations: 51     Fields:    Translation:Humans
    58. Beard CJ, Travis LB, Chen MH, Arvold ND, Nguyen PL, Martin NE, Kuban DA, Ng AK, Hoffman KE. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013 Aug 01; 119(15):2771-7. PMID: 23633409.
      Citations: 21     Fields:    Translation:Humans
    59. Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, PROSTQA Consortium Study Group. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):546-53. PMID: 23561651.
      Citations: 14     Fields:    Translation:Humans
    60. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (NCCN). Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):446-75. PMID: 23584347.
      Citations: 140     Fields:    Translation:Humans
    61. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, DePetrillo TA, Mathew P. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):540-5. PMID: 23541810; PMCID: PMC4103023.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    62. Pair ML, Du W, Rojas HD, Kanke JE, McGuire SE, Lee AK, Kuban DA, Kudchadker RJ. Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer. Med Dosim. 2013; 38(3):251-4. PMID: 23540491.
      Citations: 5     Fields:    Translation:Humans
    63. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P, American Urological Association. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013 Jan; 189(1 Suppl):S2-S11. PMID: 23234625.
      Citations: 30     Fields:    Translation:Humans
    64. Melancon AD, Lee AK, Kudchadker R, Zhang L, Tucker SL, Kuban D, Dong L. Anatomic variation and dosimetric consequences of neoadjuvant hormone therapy before radiation therapy for prostate cancer. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):329-36. PMID: 24674406.
      Citations: 1     Fields:    
    65. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46. PMID: 23102837; PMCID: PMC3840533.
      Citations: 14     Fields:    Translation:Humans
    66. Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol. 2012 Sep 11; 7:154. PMID: 22967802; PMCID: PMC3494537.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    67. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9. PMID: 22836052.
      Citations: 13     Fields:    Translation:Humans
    68. Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):1169-78. PMID: 22704703; PMCID: PMC3805837.
      Citations: 55     Fields:    Translation:Humans
    69. Fisher CM, Troncoso P, Swanson DA, Munsell MF, Kuban DA, Lee AK, Yeh SF, Frank SJ. Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy. 2012 Nov-Dec; 11(6):429-34. PMID: 22727472; PMCID: PMC3891369.
      Citations: 3     Fields:    Translation:Humans
    70. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9. PMID: 22673704; PMCID: PMC4158734.
      Citations: 5     Fields:    Translation:Humans
    71. Boonsirikamchai P, Kaur H, Kuban DA, Jackson E, Hou P, Choi H. Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach. AJR Am J Roentgenol. 2012 Mar; 198(3):W228-36. PMID: 22358019.
      Citations: 8     Fields:    Translation:Humans
    72. Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Watson W, Oudard S. Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int. 2012 Mar; 109 Suppl 2:8-13. PMID: 22257099.
      Citations: 3     Fields:    Translation:Humans
    73. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352. PMID: 22357249.
      Citations: 5     Fields:    Translation:Humans
    74. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71. PMID: 22336663.
      Citations: 4     Fields:    Translation:Humans
    75. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):e7-e13. PMID: 24674130.
      Citations: 5     Fields:    
    76. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8. PMID: 22290249.
      Citations: 11     Fields:    Translation:Humans
    77. Samuelian JM, Swanson DA, Kudchadker RJ, Pugh TJ, Kuban DA, Lee AK, Choi S, Nguyen QN, Bruno TL, Frank SJ. Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy. 2011 Dec; 3(4):183-7. PMID: 23346126; PMCID: PMC3551361.
      Citations: 3     
    78. Iyengar P, Levy LB, Choi S, Lee AK, Kuban DA. Toxicity associated with postoperative radiation therapy for prostate cancer. Am J Clin Oncol. 2011 Dec; 34(6):611-8. PMID: 21150565.
      Citations: 2     Fields:    Translation:Humans
    79. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14. PMID: 21934053; PMCID: PMC3831607.
      Citations: 86     Fields:    Translation:HumansPHPublic Health
    80. Vassiliev ON, Kudchadker RJ, Kuban DA, Frank SJ, Choi S, Nguyen Q, Lee AK. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med. 2012 Jul; 28(3):240-4. PMID: 21875820.
      Citations: 3     Fields:    Translation:Humans
    81. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20. PMID: 21074194.
      Citations: 23     Fields:    Translation:Humans
    82. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Purdy JA, Kuban D, Lee AK, Cheung MR, Thames HD, Cox JD. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1253-60. PMID: 20598811; PMCID: PMC2963659.
      Citations: 22     Fields:    Translation:HumansPHPublic Health
    83. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1310-7. PMID: 20493642.
      Citations: 82     Fields:    Translation:Humans
    84. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol. 2010 Jul; 96(1):6-12. PMID: 20400191.
      Citations: 32     Fields:    Translation:Humans
    85. Frank SJ, Kudchadker RJ, Kuban DA, De Crevoisier R, Lee AK, Cheung RM, Choi S, Tucker SL, Dong L. A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol. 2010 Apr; 33(2):173-5. PMID: 20010077.
      Citations: 3     Fields:    Translation:Humans
    86. Archambault L, Briere TM, Beaulieu L, Kuban DA, Lee A, Beddar S, P?nisch F. Toward a real-time in vivo dosimetry system using plastic scintillation detectors. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):280-7. PMID: 20231074; PMCID: PMC2889037.
      Citations: 21     Fields:    Translation:Humans
    87. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov; 182(5):2232-41. PMID: 19781717.
      Citations: 118     Fields:    Translation:Humans
    88. Kuban DA. Localized prostate cancer: the battle of treatment options enters the larger arena. Oncology (Williston Park). 2009 Sep; 23(10):867, 873. PMID: 19839428.
      Citations: 1     Fields:    Translation:Humans
    89. Anderson JF, Swanson DA, Levy LB, Kuban DA, Lee AK, Kudchadker R, Phan J, Bruno T, Frank SJ. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology. 2009 Sep; 74(3):601-5. PMID: 19589580.
      Citations: 20     Fields:    Translation:Humans
    90. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology. 2009; 77(2):75-81. PMID: 19571599; PMCID: PMC2790774.
      Citations:    Fields:    Translation:Humans
    91. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80. PMID: 19402048.
      Citations: 20     Fields:    Translation:Humans
    92. Madsen LT, Craig C, Kuban D. A multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurse. Clin J Oncol Nurs. 2009 Jun; 13(3):305-9. PMID: 19502188.
      Citations: 5     Fields:    Translation:Humans
    93. Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, Gokaslan ZL, Rhines LD, Rao G. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine. 2009 May; 10(5):414-22. PMID: 19442002.
      Citations: 15     Fields:    Translation:Humans
    94. Frank SJ, Levy LB, Kuban DA, Lee AK, Kudchadker RJ, Bruno TL, van Vulpen M, Swanson DA. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol. 2009 Apr; 181(4):1658-63; discussion 1663-4. PMID: 19233434.
      Citations: 1     Fields:    Translation:Humans
    95. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, National Comprehensive Cancer Network. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39. PMID: 19176203.
      Citations: 17     Fields:    Translation:Humans
    96. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M, Pisansky TM, Seider M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):377-82. PMID: 18947941; PMCID: PMC2905162.
      Citations: 18     Fields:    Translation:Humans
    97. Wang H, Garden AS, Zhang L, Wei X, Ahamad A, Kuban DA, Komaki R, O'Daniel J, Zhang Y, Mohan R, Dong L. Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):210-9. PMID: 18722272; PMCID: PMC2593788.
      Citations: 37     Fields:    Translation:Humans
    98. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. 2008 Dec; 72(6):1298-302; discussion 1302-4. PMID: 18672274; PMCID: PMC4020432.
      Citations: 31     Fields:    Translation:Humans
    99. O'Daniel JC, Dong L, Zhang L, Wang H, Tucker SL, Kudchadker RJ, Lee AK, Cheung R, Cox JD, Kuban DA, Mohan R. Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):274-80. PMID: 18406891.
      Citations:    Fields:    Translation:Humans
    100. Kudchadker RJ, Swanson DA, Kuban DA, Lee AK, Bruno TL, Frank SJ. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era? Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):623-7. PMID: 18410998.
      Citations: 3     Fields:    Translation:Humans
    101. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Mar 20; 358(12):1250-61. PMID: 18354103.
      Citations: 685     Fields:    Translation:Humans
    102. Frank SJ, Dong L, Kudchadker RJ, De Crevoisier R, Lee AK, Cheung R, Choi S, O'Daniel J, Tucker SL, Wang H, Kuban DA. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):813-20. PMID: 18207664.
      Citations: 23     Fields:    Translation:HumansPHPublic Health
    103. Melancon AD, O'Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, Cheung RM, de Crevoisier R, Tucker SL, Newhauser WD, Mohan R, Dong L. Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol. 2007 Nov; 85(2):251-9. PMID: 17892900; PMCID: PMC2759187.
      Citations: 6     Fields:    Translation:Humans
    104. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):67-74. PMID: 17765406.
      Citations: 376     Fields:    Translation:Humans
    105. Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1265-71. PMID: 17637398.
      Citations: 24     Fields:    Translation:Humans
    106. de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, Kudchadker RJ, Newhauser WD, Zhang L, Mohan R, Dong L. Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1529-36. PMID: 17544595.
      Citations: 8     Fields:    Translation:Humans
    107. Vassiliev ON, Kry SF, Kuban DA, Salehpour M, Mohan R, Titt U. Treatment-planning study of prostate cancer intensity-modulated radiotherapy with a Varian Clinac operated without a flattening filter. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1567-71. PMID: 17544596.
      Citations: 13     Fields:    Translation:HumansCells
    108. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007 Jun; 177(6):2151-6; discussion 2156. PMID: 17509305.
      Citations: 32     Fields:    Translation:Humans
    109. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20; 25(15):2035-41. PMID: 17513807; PMCID: PMC2670394.
      Citations: 253     Fields:    Translation:Humans
    110. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1417-23. PMID: 17418972.
      Citations: 32     Fields:    Translation:Humans
    111. Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y, Newhauser WD, Gillin M, Mohan R. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):620-9. PMID: 17236979; PMCID: PMC1945214.
      Citations: 31     Fields:    Translation:Humans
    112. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, Kudchadker RJ, Thames H, Mohan R, Kuban D. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67(4):1059-65. PMID: 17241755; PMCID: PMC2081969.
      Citations: 32     Fields:    Translation:HumansPHPublic Health
    113. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007 Jan-Mar; 6(1):2-8. PMID: 17284379.
      Citations: 12     Fields:    Translation:Humans
    114. Vance W, Tucker SL, de Crevoisier R, Kuban DA, Cheung MR. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):828-33. PMID: 17161554.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    115. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006 Dec; 68(6):1257-62. PMID: 17141830.
      Citations: 9     Fields:    Translation:Humans
    116. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):327-33. PMID: 17084558.
      Citations: 91     Fields:    Translation:Humans
    117. O'Daniel JC, Dong L, Zhang L, de Crevoisier R, Wang H, Lee AK, Cheung R, Tucker SL, Kudchadker RJ, Bonnen MD, Cox JD, Mohan R, Kuban DA. Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):883-91. PMID: 17011461.
      Citations: 14     Fields:    Translation:Humans
    118. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006 Oct 01; 107(7):1496-502. PMID: 16944536.
      Citations: 16     Fields:    Translation:Humans
    119. Kuban D, Lefkopoulos D, de Crevoisier R. [Image-guided radiotherapy by in-room CT-linear accelerator combination]. Cancer Radiother. 2006 Sep; 10(5):245-51. PMID: 16959518.
      Citations: 6     Fields:    Translation:Humans
    120. Gao S, Zhang L, Wang H, de Crevoisier R, Kuban DD, Mohan R, Dong L. A deformable image registration method to handle distended rectums in prostate cancer radiotherapy. Med Phys. 2006 Sep; 33(9):3304-12. PMID: 17022225.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    121. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006 Aug 01; 107(3):631-9. PMID: 16802288.
      Citations: 23     Fields:    Translation:Humans
    122. Cheung R, Tucker SL, Kuban DA. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):20-4. PMID: 16814948.
      Citations: 6     Fields:    Translation:Humans
    123. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):975-81. PMID: 16750319.
      Citations: 7     Fields:    Translation:Humans
    124. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006 Aug 01; 65(5):1487-93. PMID: 16750326.
      Citations: 24     Fields:    Translation:Humans
    125. Tucker SL, Zhang M, Dong L, Mohan R, Kuban D, Thames HD. Cluster model analysis of late rectal bleeding after IMRT of prostate cancer: a case-control study. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1255-64. PMID: 16504763.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    126. Kuban DA. Does postoperative adjuvant radiotherapy reduce biochemical progression after radical prostatectomy? Nat Clin Pract Urol. 2006 Feb; 3(2):70-1. PMID: 16470200.
      Citations:    Fields:    
    127. Lee CT, Dong L, Ahamad AW, Choi H, Cheung R, Lee AK, Horne DF, Breaux AJ, Kuban DA. Comparison of treatment volumes and techniques in prostate cancer radiation therapy. Am J Clin Oncol. 2005 Dec; 28(6):618-25. PMID: 16317275.
      Citations: 8     Fields:    Translation:HumansPHPublic Health
    128. Lee AK, Levy LB, Cheung R, Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys. 2005 Oct 01; 63(2):456-62. PMID: 15927415.
      Citations: 17     Fields:    Translation:Humans
    129. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1140-50. PMID: 16198506.
      Citations: 44     Fields:    Translation:Humans
    130. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2005 Sep 01; 63(1):134-40. PMID: 16111581.
      Citations: 12     Fields:    Translation:Humans
    131. Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology. 2005 Aug; 66(2):327-31. PMID: 16040084.
      Citations: 7     Fields:    Translation:Humans
    132. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen II. Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):1204-16. PMID: 15990026.
      Citations: 51     Fields:    Translation:Humans
    133. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen II. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):1195-203. PMID: 15990025.
      Citations: 105     Fields:    Translation:Humans
    134. de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD, Kuban DA. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):965-73. PMID: 15989996.
      Citations: 88     Fields:    Translation:HumansPHPublic Health
    135. Kuban DA, Dong L, Cheung R, Strom E, De Crevoisier R. Ultrasound-based localization. Semin Radiat Oncol. 2005 Jul; 15(3):180-91. PMID: 15983943.
      Citations: 11     Fields:    Translation:Humans
    136. Wang H, Dong L, O'Daniel J, Mohan R, Garden AS, Ang KK, Kuban DA, Bonnen M, Chang JY, Cheung R. Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol. 2005 Jun 21; 50(12):2887-905. PMID: 15930609.
      Citations: 172     Fields:    Translation:Humans
    137. Kuban DA, Thames HD, Shipley WU. Defining recurrence after radiation for prostate cancer. J Urol. 2005 Jun; 173(6):1871-8. PMID: 15879766.
      Citations: 3     Fields:    Translation:Humans
    138. Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):795-9. PMID: 15925452.
      Citations: 2     Fields:    Translation:Humans
    139. Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ, Shen Y, Yang Y, Chichakli R, Pisters LL. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005 May 15; 103(10):2060-6. PMID: 15822114.
      Citations: 1     Fields:    Translation:Humans
    140. Court LE, Dong L, Lee AK, Cheung R, Bonnen MD, O'Daniel J, Wang H, Mohan R, Kuban D. An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):154-63. PMID: 15850916.
      Citations: 20     Fields:    Translation:Humans
    141. Mohan R, Zhang X, Wang H, Kang Y, Wang X, Liu H, Ang KK, Kuban D, Dong L. Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1258-66. PMID: 15752908.
      Citations: 35     Fields:    Translation:Humans
    142. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):993-1002. PMID: 15752878.
      Citations: 16     Fields:    Translation:Humans
    143. Wang H, Dong L, Lii MF, Lee AL, de Crevoisier R, Mohan R, Cox JD, Kuban DA, Cheung R. Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):725-35. PMID: 15708250.
      Citations: 57     Fields:    Translation:Humans
    144. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005 Mar; 173(3):797-802. PMID: 15711272.
      Citations: 31     Fields:    Translation:Humans
    145. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):409-14. PMID: 15667960.
      Citations: 6     Fields:    Translation:Humans
    146. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):415-9. PMID: 15667961.
      Citations: 22     Fields:    Translation:Humans
    147. Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jan 01; 61(1):14-9. PMID: 15629589.
      Citations: 5     Fields:    Translation:Humans
    148. Tucker SL, Dong L, Cheung R, Johnson J, Mohan R, Huang EH, Liu HH, Thames HD, Kuban D. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1589-601. PMID: 15590191.
      Citations: 24     Fields:    Translation:HumansPHPublic Health
    149. Buyyounouski MK, Hanlon AL, Price RA, Horwitz EM, Feigenberg SJ, Pollack A. In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1664-5; author reply 1666. PMID: 15590205.
      Citations: 1     Fields:    Translation:Humans
    150. Schulz RJ, Kagan AR. Biochemical recurrence-free survival: does it relate to survival? Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1261; author reply 1261-2. PMID: 15234065.
      Citations:    Fields:    Translation:Humans
    151. Selek U, Cheung R, Lii M, Allen P, Steadham RE, Vantreese TR, Little DJ, Rosen II, Kuban D. Erectile dysfunction and radiation dose to penile base structures: a lack of correlation. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1039-46. PMID: 15234037.
      Citations: 14     Fields:    Translation:Humans
    152. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc. 2004 Jul; 96(7):939-44. PMID: 15253325; PMCID: PMC2568437.
      Citations: 7     Fields:    Translation:Humans
    153. Tucker SL, Cheung R, Dong L, Liu HH, Thames HD, Huang EH, Kuban D, Mohan R. Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):353-65. PMID: 15145148.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    154. Court LE, Dong L, Taylor N, Ballo M, Kitamura K, Lee AK, O'Daniel J, White RA, Cheung R, Kuban D. Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):412-8. PMID: 15145157.
      Citations: 13     Fields:    Translation:Humans
    155. Kuban DA, Dong L. High-dose intensity modulated radiation therapy for prostate cancer. Curr Urol Rep. 2004 Jun; 5(3):197-202. PMID: 15161568.
      Citations: 1     Fields:    Translation:Humans
    156. Kuban DA, Thames HD, Levy LB. PSA after radiation for prostate cancer. Oncology (Williston Park). 2004 May; 18(5):595-604; discussion 605, 609. PMID: 15209188.
      Citations: 1     Fields:    Translation:Humans
    157. Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA, Meyn RE. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther. 2004 Apr; 11(4):273-9. PMID: 14765130.
      Citations: 16     Fields:    Translation:HumansCells
    158. Cheung R, Tucker SL, Ye JS, Dong L, Liu H, Huang E, Mohan R, Kuban D. Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1513-9. PMID: 15050331.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    159. D'Souza WD, Thames HD, Kuban DA. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1540-8. PMID: 15050335.
      Citations: 4     Fields:    Translation:Humans
    160. O'Daniel JC, Dong L, Kuban DA, Liu H, Schechter N, Tucker SL, Rosen I. The delivery of IMRT with a single physical modulator for multiple fields: a feasibility study for paranasal sinus cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):876-87. PMID: 14967445.
      Citations: 6     Fields:    Translation:Humans
    161. Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, Rosen I. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1260-8. PMID: 14630260.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    162. Lawrence G, Crawford J. Systemic benefit of local radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1510-1; author reply 1511. PMID: 14630294.
      Citations:    Fields:    Translation:Humans
    163. Selek U, Lee A, Levy L, Kuban DA. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):963-7. PMID: 14575826.
      Citations: 1     Fields:    Translation:Humans
    164. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):915-28. PMID: 14575822.
      Citations: 75     Fields:    Translation:Humans
    165. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):929-43. PMID: 14575823.
      Citations: 27     Fields:    Translation:Humans
    166. Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol. 2003 Nov; 170(5):1860-3. PMID: 14532793.
      Citations: 8     Fields:    Translation:Humans
    167. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol. 2003 Nov; 170(5):1856-9. PMID: 14532792.
      Citations: 2     Fields:    Translation:Humans
    168. Lee HK, D'Souza WD, Yamal JM, Pollack A, Lee AK, Palmer MB, Kuban DA. Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):355-61. PMID: 12957245.
      Citations: 5     Fields:    Translation:Humans
    169. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003 Oct; 62(4):707-13. PMID: 14550448.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    170. Kuban DA, Thames HD, Levy LB. Radiation for prostate cancer: use of biochemical failure as an endpoint following radiotherapy. World J Urol. 2003 Sep; 21(4):253-64. PMID: 12923658.
      Citations: 3     Fields:    Translation:Humans
    171. Cheung R, Tucker SL, Dong L, Kuban D. Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Aug 01; 56(5):1234-40. PMID: 12873666.
      Citations: 6     Fields:    Translation:Humans
    172. Little DJ, Dong L, Levy LB, Chandra A, Kuban DA. Use of portal images and BAT ultrasonography to measure setup error and organ motion for prostate IMRT: implications for treatment margins. Int J Radiat Oncol Biol Phys. 2003 Aug 01; 56(5):1218-24. PMID: 12873664.
      Citations: 24     Fields:    Translation:Humans
    173. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):755-63. PMID: 12788182.
      Citations: 21     Fields:    Translation:Humans
    174. Thames HD, D'Souza W, Kuban DA. Dual radiobiological interpretations of retrospective clinical data: the time factor. Int J Radiat Biol. 2003 Jul; 79(7):503-9. PMID: 14530158.
      Citations:    Fields:    Translation:Humans
    175. Rosser CJ, Levy LB, Kuban DA, Chichakli R, Pollack A, Lee A, Pisters LL. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate. J Urol. 2003 Jun; 169(6):2160-5. PMID: 12771739.
      Citations: 2     Fields:    Translation:Humans
    176. Chandra A, Dong L, Huang E, Kuban DA, O'Neill L, Rosen I, Pollack A. Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys. 2003 Jun 01; 56(2):436-47. PMID: 12738318.
      Citations: 27     Fields:    Translation:Humans
    177. Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):1-6. PMID: 12694817.
      Citations: 19     Fields:    Translation:Humans
    178. Millar J, Williams S. In regard to Pollack et al., prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. IJROBP 2002;53:1097-1105. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1461; author reply 1461-2. PMID: 12654464.
      Citations:    Fields:    Translation:Humans
    179. Kagan AR, Schulz RJ. A commentary on dose escalation and bNED in prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Mar 15; 55(4):1151; author reply 1151-2. PMID: 12605997.
      Citations:    Fields:    Translation:Humans
    180. Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, Kuban DA. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1314-21. PMID: 12459352.
      Citations: 70     Fields:    Translation:Humans
    181. Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, Pisters LL. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002 Nov; 168(5):2001-5. PMID: 12394695.
      Citations: 17     Fields:    Translation:Humans
    182. Hung AY, Levy L, Kuban DA. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis. Cancer J. 2002 Nov-Dec; 8(6):440-4. PMID: 12500852.
      Citations: 4     Fields:    Translation:Humans
    183. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002 Nov 01; 54(3):677-85. PMID: 12377318.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    184. Pollack A, Kuban DA, Zagars GK. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):22-30; discussion 30-1. PMID: 12231041.
      Citations: 3     Fields:    Translation:Humans
    185. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1097-105. PMID: 12128107.
      Citations: 287     Fields:    Translation:HumansCTClinical Trials
    186. Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol. 2002 Aug; 168(2):536-41. PMID: 12131304.
      Citations: 10     Fields:    Translation:Humans
    187. Huang E, Dong L, Chandra A, Kuban DA, Rosen II, Evans A, Pollack A. Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):261-8. PMID: 12023128.
      Citations: 49     Fields:    Translation:Humans
    188. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol. 2001 Sep; 166(3):947-52. PMID: 11490252.
      Citations: 24     Fields:    Translation:Humans
    189. Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul J, Pollack A, Raghavan D, Ray P, Roach M, Steinberg G, Stone N, Thompson I, Vogelzang N, Vijayakumar S. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer. 2001 Jun 20; 96(3):198-209. PMID: 11410889.
      Citations: 4     Fields:    Translation:Humans
    190. Incognito LS, Cazares LH, Schellhammer PF, Kuban DA, Van Dyk EO, Moriarty RP, Wright GL, Somers KD. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy. Int J Oncol. 2000 Oct; 17(4):761-9. PMID: 10995889.
      Citations: 4     Fields:    Translation:HumansCells
    191. Schellhammer PF, Moriarty R, Bostwick D, Kuban D. Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology. 2000 Sep 01; 56(3):436-9. PMID: 10962309.
      Citations: 5     Fields:    Translation:Humans
    192. Davis JW, Kolm P, Wright GL, Kuban D, El-Mahdi A, Schellhammer PF. The durability of external beam radiation therapy for prostate cancer: can it be identified? J Urol. 1999 Sep; 162(3 Pt 1):758-61. PMID: 10458360.
      Citations:    Fields:    Translation:Humans
    193. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999 May 05; 281(17):1598-604. PMID: 10235152.
      Citations: 69     Fields:    Translation:Humans
    194. Lawton CA, Grignon D, Newhouse JH, Schellhammer PF, Kuban DA. Prostatic carcinoma. Radiographics. 1999 Jan-Feb; 19(1):185-203. PMID: 9925399.
      Citations:    Fields:    Translation:Humans
    195. Kuban DA, El-Mahdi AM, Schellhammer PF. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? Semin Radiat Oncol. 1998 Apr; 8(2):72-80. PMID: 9516587.
      Citations: 2     Fields:    Translation:Humans
    196. Hong JJ, Yacoub SF, Blevins JC, Kuban DA, el-Mahdi AM. High dose rate vaginal brachytherapy in early stage endometrial carcinoma: preliminary analysis. Am J Clin Oncol. 1997 Jun; 20(3):254-8. PMID: 9167748.
      Citations: 1     Fields:    Translation:Humans
    197. Schellhammer PF, el-Mahdi AM, Kuban DA, Wright GL. Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir. Urol Clin North Am. 1997 May; 24(2):407-14. PMID: 9126238.
      Citations:    Fields:    Translation:Humans
    198. Kuban DA, el-Mahdi AM, Schellhammer PF. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):307-16. PMID: 7538499.
      Citations: 6     Fields:    Translation:Humans
    199. Kuban DA, el-Mahdi AM, Schellhammer PF. Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer. 1995 May 01; 75(9):2373-82. PMID: 7536125.
      Citations: 2     Fields:    Translation:Humans
    200. Kim JA, Kuban DA, el-Mahdi AM, Schellhammer PF. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology. 1995 Feb; 194(2):545-9. PMID: 7529936.
      Citations: 7     Fields:    Translation:Humans
    201. Schellhammer PF, Kuban DA, el-Mahdi AM. Treatment of clinical local failure after radiation therapy for prostate carcinoma. J Urol. 1993 Dec; 150(6):1851-5. PMID: 8230518.
      Citations: 8     Fields:    Translation:Humans
    202. Kuban DA, el-Mahdi AM, Schellhammer PF. Prognostic significance of post-irradiation prostate biopsies. Oncology (Williston Park). 1993 Feb; 7(2):29-38; discussion 40, 43-4, 47. PMID: 7679918.
      Citations: 1     Fields:    Translation:Humans
    203. Yu J, Shaeffer J, Zhu A, Kuban DA, el-Mahdi AM, Philput CB. Flow cytometric DNA content and clinical outcome in patients with non-small cell lung cancer given postoperative radiation therapy. Cytometry. 1993; 14(4):428-32. PMID: 8390343.
      Citations: 1     Fields:    Translation:Humans
    204. el-Mahdi AM, Kuban DA. Treatment of carcinoma of the prostate in the 1990's. Compr Ther. 1992 Jun; 18(6):10-4. PMID: 1511588.
      Citations:    Fields:    Translation:Humans
    205. Kuban DA, el-Mahdi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 1992; 24(3):409-14. PMID: 1399724.
      Citations: 5     Fields:    Translation:Humans
    206. Shaeffer J, Tegeler JA, Kuban DA, Philput CB, el-Mahdi AM. Nuclear roundness factor and local failure from definitive radiation therapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 1992; 24(3):431-4. PMID: 1399727.
      Citations:    Fields:    Translation:HumansCells
    207. Kuban DA, el-Mahdi AM. The earlier the better or unnecessary therapy? Int J Radiat Oncol Biol Phys. 1992; 24(3):569-70. PMID: 1399746.
      Citations:    Fields:    Translation:Humans
    208. Anderson RS, el-Mahdi AM, Kuban DA, Higgins EM. Brain metastases from transitional cell carcinoma of urinary bladder. Urology. 1992 Jan; 39(1):17-20. PMID: 1728790.
      Citations: 19     Fields:    Translation:Humans
    209. Schellhammer PF, Kuban DA, el-Mahdi AM. Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy. Urol Clin North Am. 1991 Aug; 18(3):485-99. PMID: 1877111.
      Citations:    Fields:    Translation:Humans
    210. Kuban DA, Schellhammer PF, el-Mahdi AM. Hemibody irradiation in advanced prostatic carcinoma. Urol Clin North Am. 1991 Feb; 18(1):131-7. PMID: 1704159.
      Citations: 1     Fields:    Translation:Humans
    211. Schellhammer PF, el-Mahdi AM, Kuban DA. Local failure and related complications after definitive treatment of clinical stage C carcinoma of the prostate by irradiation or surgery. Semin Urol. 1990 Nov; 8(4):232-46. PMID: 2284530.
      Citations:    Fields:    Translation:Humans
    212. Kuban DA, el-Mahdi AM, Schellhammer PF. I-125 interstitial implantation for prostate cancer. What have we learned 10 years later? Cancer. 1989 Jun 15; 63(12):2415-20. PMID: 2720587.
      Citations: 4     Fields:    Translation:Humans
    213. Kuban DA, el-Mahdi AM, Schellhammer PF. Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer. 1989 Jun 15; 63(12):2421-5. PMID: 2720588.
      Citations: 6     Fields:    Translation:Humans
    214. Kuban DA, Delbridge T, el-Mahdi AM, Schellhammer PF. Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate. J Urol. 1989 Mar; 141(3):572-4. PMID: 2465419.
      Citations: 5     Fields:    Translation:Humans
    215. Schellhammer PF, Whitmore RB, Kuban DA, el-Mahdi AM, Ladaga LA. Morbidity and mortality of local failure after definitive therapy for prostate cancer. J Urol. 1989 Mar; 141(3):567-71. PMID: 2918594.
      Citations: 2     Fields:    Translation:Humans
    216. Kuban DA, el-Mahdi AM, Schellhammer PF. Mortality in prostatic carcinoma. Urology. 1989 Jan; 33(1):1-5. PMID: 2911922.
      Citations:    Fields:    Translation:Humans
    217. Kuban D, el-Mahdi A, Schellhammer P. Fruit for thought. Int J Radiat Oncol Biol Phys. 1988 Sep; 15(3):796-7. PMID: 3417498.
      Citations:    Fields:    Translation:Humans
    218. Kuban DA, el-Mahdi AM, Schellhammer PF. Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology. 1987 Nov; 30(5):420-6. PMID: 3118547.
      Citations: 15     Fields:    Translation:Humans
    219. Kuban DA, el-Mahdi AM, Schellhammer PF. The effect of TURP on prognosis in prostatic carcinoma. Int J Radiat Oncol Biol Phys. 1987 Nov; 13(11):1653-9. PMID: 3667372.
      Citations: 3     Fields:    Translation:Humans
    220. Kuban DA, el-Mahdi AM, Sigfred SV, Schellhammer PF, Babb TJ. Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology. 1986 Nov; 28(5):364-9. PMID: 3787893.
      Citations: 9     Fields:    Translation:Humans
    221. el-Mahdi AM, Kuban DA. Controversies in the treatment of carcinoma of the prostate. Compr Ther. 1986 Aug; 12(8):33-6. PMID: 3742995.
      Citations:    Fields:    Translation:Humans
    222. el-Mahdi AM, Kuban DA, Schellhammer PF. The treatment of choice for localized poorly differentiated adenocarcinoma of the prostate. Am J Clin Oncol. 1985 Dec; 8(6):477-80. PMID: 4083266.
      Citations:    Fields:    Translation:Humans
    223. Kuban DA, el-Mahdi AM, Schellhammer PF, Babb TJ. The effect of transurethral prostatic resection on the incidence of osseous prostatic metastasis. Cancer. 1985 Aug 15; 56(4):961-4. PMID: 4016689.
      Citations: 4     Fields:    Translation:Humans
    224. The Roach/Kurhanewicz/Carroll article reviewed. Oncology. 15:1415-1416.
    225. Genitourinary cancer survivorship management. 95-124.
    226. Reconsidering the case for brachytherapy plus EBRT in high-risk prostate cancer. Oncology. 22:1006-1012.
    227. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Practical Radiation Oncology. 2.
    228. Localized prostate cancer. Oncology. 23.
    229. An organ-preserving alternative to laryngectomy for salvage of glottic cancer failing radiotherapy. Endocurietherapy/Hyperthermia Oncology. 12:199-204.
    230. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer. BMC Cancer. 15.
    231. Prostate Cancer. 1037-1097.
    232. Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy.
    233. Salvage radiotherapy or observation after radical prostatectomy in the PSA era. American Journal of Hematology/ Oncology. 8.
    234. Predictors of breast radiotherapy plan modifications. Breast Diseases. 26:241-242.
    235. Prostate cancer. 377-402.
    236. Assessing the quality of a radiation oncology case-based peer-review program in an integrated academic and community cancer center network. Journal of Oncology Practice. 12:e476-e486.
    237. The Merrick/Wallner/Butler et al article reviewed. Oncology. 20:522-523.
    238. Anatomic variation and dosimetric consequences of neoadjuvant hormone therapy before radiation therapy for prostate cancer. Practical Radiation Oncology. 3:329-336.
    239. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials.
    240. Prostate Cancer. e51.1-e51.85.
    241. Local control after radiation for prostatic carcinoma. Seminars in Radiation Oncology. 3:221-229.
    242. Therapeutic strategies for local failure after radiation therapy for stage A-C carcinoma of the prostate. Problems in Urology. 7:205-214.
    243. Lymph nodepositive prostate cancer. ONCOLOGY (United States). 27.
    244. In Reply to Drs. Pickles and Williams. International Journal of Radiation Oncology Biology Physics. 67:319.
    245. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy. International Journal of Radiation Oncology Biology Physics. 96:770-777.
    246. Prostate cancer. 35-43.
    247. In Reply to Drs. Schulz and Kagan. International Journal of Radiation Oncology Biology Physics. 71:1288.
    248. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU International. 117:469-477.
    249. The influence of age and comorbidity on the benefit of adding androgen deprivation to dose-escalated radiation in men with intermediate-risk prostate cancer. American Journal of Clinical Oncology: Cancer Clinical Trials.
    250. Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. American Journal of Men's Health. 11:73-81.
    KUBAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (421)
    Explore
    _
    Co-Authors (104)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _